This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 11, 2013 /PRNewswire/ --
NI Research has released the February issue of
NeuroPerspective. The issue features a comprehensive review of ALS, and the continuing but frustrating search for a genuinely useful treatment for the treatment of this devastating illness.
"Just as Alzheimer's slowly erases memory and personality, ALS gradually destroys muscle control, leaving patients almost invariably doomed to death from respiratory failure. The Phase III failure of
Biogen-Idec/Knopp's dexpramipexole has provided yet another reminder of how difficult it has been to achieve any headway against ALS," said
Harry Tracy, Ph.D., editor and publisher of NeuroPerspective.
The 21-page issue includes:
1) An overview of the pathophysiology of ALS; a reconsideration of SOD1 anomalies in recapitulating phenotype rather than genotype; and the growing interest in therapeutic approaches that address immunoreactive and inflammatory factors.
2) Programs covered in the review include those from
Isis Pharmaceuticals, Neuraltus, Newron, NeuralStem, BrainStorm Cell Therapeutics, Cambria Pharmaceuticals, Regenesance, Amorfix, KineMed, and
Cytokinetics, plus many others. The prominent role of
ALS TDI in ALS research is noted, as is its intriguing program assessing the potential value of
Novartis' Gilenya as an ALS therapeutic.
3) Other coverage and commentary in the February issue includes:
Genentech's licensing of the Afraxis PAK program
Executive Turbulence at AstraZeneca and EnVivo Pharmaceuticals
Tevaand Tire Irons: The Risk of Going MAD
A brief summary review of
Regenesance, developing therapeutics for disorders associated with complement activation.
The February issue of
NeuroPerspective is being made available as a